scholarly journals Cholinergic agonists reduce blood pressure in a mouse model of systemic lupus erythematosus

2017 ◽  
Vol 5 (7) ◽  
pp. e13213 ◽  
Author(s):  
Amber S. Fairley ◽  
Keisa W. Mathis
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Blood Pressure ◽  
Mouse Model ◽  
Lupus Erythematosus ◽  
Reduce Blood Pressure ◽  
Systemic Lupus ◽  
Cholinergic Agonists

scholarly journals Tumor Necrosis Factor-α Antagonist Etanercept Decreases Blood Pressure and Protects the Kidney in a Mouse Model of Systemic Lupus Erythematosus

Hypertension ◽  
2010 ◽  
Vol 56 (4) ◽  
pp. 643-649 ◽  
Author(s):  
Marcia Venegas-Pont ◽  
Michaele B. Manigrasso ◽  
Samira C. Grifoni ◽  
Babbette B. LaMarca ◽  
Christine Maric ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Blood Pressure ◽  
Tumor Necrosis Factor ◽  
Mouse Model ◽  
Lupus Erythematosus ◽  
Tumor Necrosis ◽  
Tumor Necrosis Factor Α ◽  
Systemic Lupus ◽  
Factor Α ◽  
Necrosis Factor

scholarly journals Rosiglitazone decreases blood pressure and renal injury in a female mouse model of systemic lupus erythematosus

2009 ◽  
Vol 296 (4) ◽  
pp. R1282-R1289 ◽  
Author(s):  
Marcia Venegas-Pont ◽  
Julio C. Sartori-Valinotti ◽  
Christine Maric ◽  
Lorraine C. Racusen ◽  
Porter H. Glover ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Blood Pressure ◽  
Mouse Model ◽  
Lupus Erythematosus ◽  
Renal Injury ◽  
Female Mouse ◽  
Therapeutic Option ◽  
Peroxisome Proliferator ◽  
Systemic Lupus ◽  
Pparγ Agonist

Women with systemic lupus erythematosus (SLE) exhibit a high prevalence of hypertension and renal injury. Rosiglitazone (Rosi), a peroxisome proliferator activator receptor gamma (PPARγ) agonist, has renal protective and antihypertensive effects. We tested whether Rosi ameliorates hypertension and renal injury in a female mouse model of SLE (NZBWF1). Thirty-week-old SLE and control (NZW/LacJ) mice ( n ≥ 6/group) were fed Rosi (5 mg·kg−1·day−1in standard chow) or standard chow for 4 wk. SLE mice had increased blood pressure (BP in mmHg) compared with controls (139 ± 4 vs. 111 ± 4, P < 0.05). Rosi treatment lowered BP in SLE mice (127 ± 4, P < 0.05) but not in controls (111 ± 4). Urinary albumin (μg/mg creatinine) was increased in SLE mice compared with controls (12,396 ± 6,525 vs. 50 ± 6) and reduced with Rosi treatment (148 ± 117). Glomerulosclerosis (% of glomeruli with sclerosis) was reduced in Rosi-treated SLE mice (4.2 ± 1.6 vs. 0.4 ± 0.3, P < 0.05). Renal monocyte/macrophage numbers (cell number/1,320 points counted) were reduced in SLE mice treated with Rosi (32.6 ± 11.0 vs. 10.6 ± 3.6, P < 0.05) but unchanged in controls (3.7 ± 1.6 vs. 3.7 ± 2.0). Renal osteopontin expression, a cytokine-regulating macrophage recruitment, was reduced in Rosi-treated SLE mice. Urinary endothelin (in pg/mg creatinine) was increased in SLE mice compared with controls (1.9 ± 0.59 vs. 0.6 ± 0.04, P < 0.05) and reduced in SLE mice treated with Rosi (0.8 ± 0.11, P < 0.05). PPARγ protein expression in the renal cortex was significantly lower in SLE mice compared with controls and was unaffected by Rosi. These data suggest that Rosi may be an important therapeutic option for the treatment of SLE hypertension and renal injury.

scholarly journals The PPARgamma Agonist Rosiglitazone Decreases Blood Pressure and Renal Injury in a Female Mouse Model of Systemic Lupus Erythematosus

2008 ◽  
Vol 22 (S1) ◽  
Author(s):  
Marcia Venegas‐Pont ◽  
Christine Maric ◽  
Gerald R. McLemore ◽  
Porter Glover ◽  
Michae J. Ryan
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Blood Pressure ◽  
Mouse Model ◽  
Lupus Erythematosus ◽  
Renal Injury ◽  
Female Mouse ◽  
Systemic Lupus

scholarly journals Impact of early life ovariectomy on blood pressure and body composition in a female mouse model of systemic lupus erythematosus

2014 ◽  
Vol 307 (8) ◽  
pp. R990-R997 ◽  
Author(s):  
Emily L. Gilbert ◽  
Michael J. Ryan
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Blood Pressure ◽  
Body Composition ◽  
Body Weight ◽  
Cardiovascular Risk ◽  
Mouse Model ◽  
Lupus Erythematosus ◽  
Early Life ◽  
Systemic Lupus ◽  
Autoantibody Production

Because of the preponderance of women affected by the chronic autoimmune disease systemic lupus erythematosus (SLE), estrogen is thought to contribute to SLE disease progression. This is supported by evidence from experimental animal models of SLE showing that removal of estrogen in young female mice delays autoantibody production and renal injury and lengthens survival. Blood pressure and changes in body composition are important cardiovascular risk factors that can be regulated by estrogens. Because cardiovascular disease is the leading cause of death in patients with SLE, we used an established female mouse model of SLE (NZBWF1) to test whether early life removal of estrogen impacts the development of hypertension and changes in body composition commonly associated with SLE. Eight-week-old female SLE and control mice (NZW/LacJ) underwent either a sham operation or ovariectomy. Body weight, body composition (fat and lean masses), and renal injury (albuminuria) were monitored until mice reached 34 wk of age, at which time mean arterial pressure was assessed in conscious animals by a carotid catheter. Early life removal of the ovaries delayed the onset of autoantibody production and albuminuria while causing an increase in body weight and fat mass. Blood pressure in the adult was not altered by early life removal of the ovaries. These data suggest that estrogens may have a permissive role for the development of SLE while helping to maintain normal body weight and composition, which is associated with reduced cardiovascular risk.

scholarly journals Abrogated AID Function Prolongs Survival and Diminishes Renal Pathology in the BXSB Mouse Model of Systemic Lupus Erythematosus

2020 ◽  
Vol 204 (5) ◽  
pp. 1091-1100 ◽  
Author(s):  
Jing Zhu ◽  
Alayna N. Hay ◽  
Ashley A. Potter ◽  
Madison W. Richwine ◽  
Thomas Sproule ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Mouse Model ◽  
Lupus Erythematosus ◽  
Renal Pathology ◽  
Systemic Lupus ◽  
Bxsb Mouse

scholarly journals 6 Efficacy of cenerimod, a selective S1P1 receptor modulator, in the MRL/lpr mouse model of systemic lupus erythematosus

2019 ◽  
Author(s):  
Marianne M Martinic ◽  
Sylvie Froidevaux ◽  
Estelle Gerossier-Creusat ◽  
Enrico Vezzali ◽  
Anna Stalder ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Mouse Model ◽  
Lupus Erythematosus ◽  
Systemic Lupus ◽  
S1p1 Receptor ◽  
Receptor Modulator

scholarly journals Heat shock protein 90 inhibition by 17-DMAG lessens disease in the MRL/lpr mouse model of systemic lupus erythematosus

2012 ◽  
Vol 9 (3) ◽  
pp. 255-266 ◽  
Author(s):  
Samuel K Shimp ◽  
Cristen B Chafin ◽  
Nicole L Regna ◽  
Sarah E Hammond ◽  
Molly A Read ◽  
...  
Keyword(s):  
Systemic Lupus Erythematosus ◽  
Heat Shock ◽  
Mouse Model ◽  
Heat Shock Protein ◽  
Lupus Erythematosus ◽  
Heat Shock Protein 90 ◽  
Systemic Lupus

P4450Atherosclerosis in women with systemic lupus erythematosus with and without nephritis

2019 ◽  
Vol 40 (Supplement_1) ◽  
Author(s):  
T Panafidina ◽  
T V Popkova ◽  
D S Novikova
Keyword(s):  
Risk Factors ◽  
Systemic Lupus Erythematosus ◽  
Blood Pressure ◽  
Disease Activity ◽  
Risk Score ◽  
Lupus Erythematosus ◽  
Framingham Risk Score ◽  
Systemic Lupus ◽  
Framingham Risk ◽  
Coronary Events

Abstract Background Nephritis in systemic lupus erythematosus (SLE) is a factor contributing to early development of atherosclerosis (AS). Objectives The aim of the study is to determine differences in cardiovascular risk factors and AS in SLE pts with and without lupus nephritis (LN). Methods The study included 162 females, age 35 [26–43] years (median [interquartile range 25–75%])) with SLE (ACR,1997). We divided SLE pts on two groups, comparable in age: the 1st group is the pts with LN (n=84, 52%), the 2nd - without LN (n=78, 48%). We considered traditional factors of cardiovascular disease (CVD): (smoking, family history of CVD, blood pressure, cholesterol (total, HDL, LDL) and triglyceride (TG) levels, body mass index, diabetes mellitus) and SLE-related factors (age at onset, duration, clinical features, SLE Disease Activity Index (SLEDAI-2K) and the Systemic Lupus International Collaborating Clinics damage index (SLICC/DI), treatment with steroids); intima-media thickness (IMT) and the 10-year risk for coronary events. Carotid intima-media wall thickness of common carotid arteries was measured by high resolution B-mode ultrasound. The 10-year risk for coronary events was estimated by the Framingham risk equation. Results Median SLE duration was 8,0 [2,3–17,0] years, SLEDAI 2K – 8 [3–16], SLICC/DI score – 2 [0–3], duration of prednisone treatment – 72 [26–141] months. SLE pts from the 1st group had higher prevalence of hypertension (61% vs 36%, p<0,01), systolic blood pressure (130 [110–150] vs 120 [110–130]mm Hg, p<0,01), diastolic blood pressure (80 [70–95] vs 70 [70–80] mm Hg, p<0,05), TG concentration (136 [98–184] vs 100 [61–162] mg/dl, p<0,01), Framingham Risk Score (5 [1–30] vs 1 [1–27]%, p<0,05), SLEDAI-2K (12 [5–19] vs 4 [2–10], p<0,ehz745.08501), SLICC/DI score (2 [0–4] vs 0 [0–2], p<0,01), prednisone therapy duration (95 [26–192] vs 44 [14–98] months, p<0,05), prednisone cumulative dose (34,4 [13,6–82,5] vs 15,7 [6,2–35,2] g, p<0,001), mean IMT (0,73 [0,65–0,83] vs 0,67 [0,61–0,75] mm, p<0,01), than the pts from the 2nd group. There is no difference in CVD frequency in these groups (17% vs 8%, p=0,084). Conclusions SLE patients with and without LN had no difference in frequency of clinical manifestations of AS (CVD), but had a greater value of mean IMT, Framingham Risk Score and a higher incidence of both traditional (hypertension, TG concentration) and SLE-related (disease activity, prednisone therapy) risk factors for AS.

Sign in / Sign up

Export Citation Format

Share Document